This site is intended for healthcare professionals

Niercelcarcinoom, Oncologie

Wat is de rol van adjuvante therapie voor hoog-risico RCC patiënten anno 2022?

User Validation

In order to access this resource you must validate that you're an HCP

  • Please enter your last name and 8 first number of your INAMI number to validate your HCP status.
  • Please enter your email to receive news and updates from Ipsen. This is optional but you can unsubscribe at any time using the link at the bottom of all of our marketing emails.

DR-BE-000279 28/06/2022

You might also be interested in…

Oncologie

Presentatie ESMO 2023 Highlights – Niercelcarcinoom

Presentatie ESMO 2023 Highlights – Niercelcarcinoom
Oncologie

Cross-Border Vision on ASCO (GU) Data in aRCC – 1L aRCC (Prof. Beuselinck)

Presentatie van prof. Beuselinck (Leuven University Hospital) over 1L systemische behandeling bij aRCC tijdens het wetenschappelijke event Cross-Border Vision on ASCO (GU) Data in aRCC
Ipsen Group Ipsen NV/SA Guldensporenpark 87 9820 Merelbeke Belgium